242 related articles for article (PubMed ID: 11712025)
1. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
Sami N; Bhol KC; Razzaque Ahmed A
Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
[TBL] [Abstract][Full Text] [Related]
4. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
[TBL] [Abstract][Full Text] [Related]
7. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
[TBL] [Abstract][Full Text] [Related]
8. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
Daoud Y; Amin KG; Mohan K; Ahmed AR
Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
[TBL] [Abstract][Full Text] [Related]
9. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
10. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data.
Engineer L; Ahmed AR
J Am Acad Dermatol; 2001 Jan; 44(1):83-8. PubMed ID: 11148470
[TBL] [Abstract][Full Text] [Related]
11. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
12. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
Ahmed AR
Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
[TBL] [Abstract][Full Text] [Related]
13. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid.
Gaitanis G; Alexis I; Pelidou SH; Gazi IF; Kyritsis AP; Elisaf MS; Bassukas ID
Eur J Dermatol; 2012; 22(3):363-9. PubMed ID: 22548754
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
15. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid.
Mazzi G; Raineri A; Zanolli FA; Da Ponte C; De Roia D; Santarossa L; Guerra R; Orazi BM
Transfus Apher Sci; 2003 Feb; 28(1):13-8. PubMed ID: 12620264
[TBL] [Abstract][Full Text] [Related]
16. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
Chrissafidou A; Malek M; Musch E
Z Gastroenterol; 2007 Jul; 45(7):605-8. PubMed ID: 17620224
[TBL] [Abstract][Full Text] [Related]
17. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up.
Ahmed AR; Gürcan HM
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1074-83. PubMed ID: 21819451
[TBL] [Abstract][Full Text] [Related]
18. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
[TBL] [Abstract][Full Text] [Related]
20. [Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids].
Boughrara Z; Ingen-Housz-Oro S; Legrand P; Duong TA; Roujeau JC
Ann Dermatol Venereol; 2010 May; 137(5):345-51. PubMed ID: 20470914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
